Orforglipron Dosing Guide: Oral GLP-1 Titration to 6, 12, and 36 mg
Orforglipron dosage explained from ATTAIN-1 and ACHIEVE: start at 1 mg, escalate every 4 weeks to maintenance 6 mg, 12 mg, or 36 mg once daily. Oral GLP-1 dosing without food/water restrictions.
PeptIQ Team
Peptide Research & Education
PeptIQ app
Log your dosing protocol in PeptIQ
Turn this guide into a living protocol — doses, vials, and history in one place.
Under 25? Talk to a licensed clinician and get baseline labs before starting anything. Why we say this · Labs checklist
# Orforglipron Dosing Guide: Oral GLP-1 Titration to 6, 12, and 36 mg
> Note: PeptIQ is not a medical provider. Orforglipron is an investigational oral GLP-1 receptor agonist. Doses reflect Phase 3 trial designs and public disclosures — not a prescription.
Orforglipron (LY3502970) is the oral GLP-1 story people keep comparing to injectable semaglutide and tirzepatide — and to oral semaglutide's awkward fasting rules. It is a once-daily small-molecule GLP-1 receptor agonist taken as a capsule, without the food-and-water gymnastics Rybelsus requires.
Quick Answer: Orforglipron Dosage
Phase
Dose pattern
Start
1 mg once daily
Escalation
Step up about every 4 weeks
Obesity maintenance (ATTAIN-1)
6 mg, 12 mg, or 36 mg once daily
Diabetes example (ACHIEVE-1)
Maintenance arms including 3 mg, 12 mg, 36 mg in public descriptions
ATTAIN-1 Titration Ladder (Obesity)
ATTAIN-1 (NCT05869903) was a 72-week Phase 3 trial in adults with obesity or overweight plus comorbidity, without diabetes. Participants started at 1 mg daily and escalated at four-week intervals to their randomized maintenance dose:
Target maintenance
Typical step path described publicly
6 mg
1 mg → 3 mg → 6 mg
12 mg
1 mg → 3 mg → 6 mg → 12 mg
36 mg
1 mg → 3 mg → 6 mg → 12 mg → 24 mg → 36 mg
Dose reductions were generally reserved for GI tolerability after other mitigations failed (per public trial descriptions).
Weight-Loss Results People Cite
Public ATTAIN-1 summaries (efficacy-style figures) reported roughly:
Arm
Approx. mean weight change @ 72 weeks
6 mg
~−8%
12 mg
~−9%
36 mg
~−12%
Placebo
~−1%
Treatment-policy / other estimands in media coverage sometimes quote slightly different percentages (for example ~7.5–11% ranges). Prefer the NEJM table for citations. Directionally: higher maintenance dose → larger mean loss, with classic GLP-1 GI adverse events.
Why Oral Dosing Changes Tracking
Injectable weekly drugs create a "dose day" narrative. Orforglipron is daily, which means:
Missed-dose patterns matter more
GI symptoms may be steadier rather than once-weekly spikes
Adherence logging should be daily checkboxes, not only weekly entries
No reconstitution math — but titration discipline still makes or breaks tolerability
Orforglipron vs Injectable GLP-1s
Orforglipron
Semaglutide / tirzepatide injectables
Route
Oral capsule daily
Weekly SC (mostly)
Food rules
No Rybelsus-style empty-stomach ritual (per public Lilly messaging)
Not applicable for injectables
Status
Investigational / late-stage
Multiple approved brands
Best SEO intent
"oral GLP-1 dosing"
"ozempic dose" / "mounjaro titration"
What to Track
Current daily mg and last escalation date
Missed doses per week
Nausea / constipation scores
Protein grams and training
Average weight + waist
Reason for any dose hold
FAQ
Q: What is the highest orforglipron dose?
A: In ATTAIN-1 obesity Phase 3, the top randomized maintenance dose was 36 mg daily.
Q: Do I need to take orforglipron fasting?
A: Public Lilly communications emphasize once-daily use without the food/water restrictions required for oral semaglutide. Always follow the eventual label if approved.
Q: How fast can I titrate?
A: Trial designs used ~4-week steps. Faster DIY escalation is a common way people get knocked out by nausea.
Q: Is orforglipron a peptide?
A: It is a small-molecule GLP-1 receptor agonist (non-peptide), which is why oral bioavailability is feasible without peptide injection.
Bottom Line
Orforglipron dosing is a daily oral titration story: start 1 mg, climb every four weeks, land on 6 / 12 / 36 mg maintenance in obesity Phase 3. That ladder is the SEO asset — clear, citable, and easy to turn into a tracking template.
